Q3 2024 Earnings Call Transcript November 8, 2024 Operator: Good morning and welcome to Ocugen’s Third Quarter 2024 Financial ...

Ocugen ( OCGN -6.48%) Q3 2024 Earnings Call Nov 08, 2024, 8:30 a.m. ET Good morning and welcome to Ocugen's third quarter 2024 financial results and business update. [Operator instructions] I will now ...

“The third quarter was a period of important milestones and outstanding progress for IMUNON, driven largely by presentation ... market potential for the Company’s products, if approved, the potential ...

Agbiz and South Africa Wine recently held a media day at Picardi Farm, uniting industry leaders to discuss challenges, and innovations, and foster collaboration in South Africa's wine and agricultural ...

The ASH Annual Meeting is one of the largest gatherings of the international hematology community, aggregating the latest scientific research on the pathogenesis and clinical treatment of hematologic ...

Prilenia Therapeutics B.V., a biopharmaceutical company focused on developing novel therapeutics to treat neurodegenerative ...

Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) An ...

Collaboration Revenue: Collaboration revenue generated through the company's collaboration, option, and license agreement with Bristol-Myers Squibb was $0.8 million for the three months ended ...

Results from an LTE study of patients with Waldenström macroglobulinemia (WM) from the Phase 3 ASPEN study, with a median ...

As a woman prepares to pitch her friend to an audience of roughly 200 eager singles, a few of their pals skip around the room ...

Working as an investment banker means knowing more than finance terms. Inside Wall Street's coded language for everyday ...

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptanceCompany also announces FDA End-of-Phase 2 in-person meeting ...